|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0017262,
umls-concept:C0087111,
umls-concept:C0185117,
umls-concept:C0205217,
umls-concept:C0205276,
umls-concept:C0205373,
umls-concept:C0332206,
umls-concept:C0754728,
umls-concept:C0949691,
umls-concept:C1411976,
umls-concept:C1456820,
umls-concept:C2911684
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2005-7-4
|
|
pubmed:abstractText |
Abnormal host defense against pathogens has been implicated in the pathogenesis of spondylarthropathy (SpA), a disease characterized by abundant synovial infiltration with innate immune cells. Given the role of Toll-like receptors (TLRs) in activation of innate inflammation and the occurrence of TLR-dependent infections after tumor necrosis factor alpha (TNFalpha) blockade treatment, the present study was undertaken to analyze TLRs and their modulation by TNFalpha blockade in SpA.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antirheumatic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G,
http://linkedlifedata.com/resource/pubmed/chemical/Lipopolysaccharides,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Cell Surface,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Tumor Necrosis Factor,
http://linkedlifedata.com/resource/pubmed/chemical/TLR2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/TLR4 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/TNFR-Fc fusion protein,
http://linkedlifedata.com/resource/pubmed/chemical/Toll-Like Receptor 2,
http://linkedlifedata.com/resource/pubmed/chemical/Toll-Like Receptor 4,
http://linkedlifedata.com/resource/pubmed/chemical/Toll-Like Receptors,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/infliximab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0004-3591
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
52
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2146-58
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15986373-Adult,
pubmed-meshheading:15986373-Aged,
pubmed-meshheading:15986373-Aged, 80 and over,
pubmed-meshheading:15986373-Antibodies, Monoclonal,
pubmed-meshheading:15986373-Antirheumatic Agents,
pubmed-meshheading:15986373-Arthritis, Rheumatoid,
pubmed-meshheading:15986373-Down-Regulation,
pubmed-meshheading:15986373-Female,
pubmed-meshheading:15986373-Flow Cytometry,
pubmed-meshheading:15986373-Humans,
pubmed-meshheading:15986373-Immunoenzyme Techniques,
pubmed-meshheading:15986373-Immunoglobulin G,
pubmed-meshheading:15986373-Leukocytes, Mononuclear,
pubmed-meshheading:15986373-Lipopolysaccharides,
pubmed-meshheading:15986373-Macrophages,
pubmed-meshheading:15986373-Male,
pubmed-meshheading:15986373-Membrane Glycoproteins,
pubmed-meshheading:15986373-Middle Aged,
pubmed-meshheading:15986373-Osteoarthritis, Knee,
pubmed-meshheading:15986373-Receptors, Cell Surface,
pubmed-meshheading:15986373-Receptors, Tumor Necrosis Factor,
pubmed-meshheading:15986373-Spondylarthropathies,
pubmed-meshheading:15986373-Synovial Membrane,
pubmed-meshheading:15986373-Toll-Like Receptor 2,
pubmed-meshheading:15986373-Toll-Like Receptor 4,
pubmed-meshheading:15986373-Toll-Like Receptors,
pubmed-meshheading:15986373-Treatment Outcome,
pubmed-meshheading:15986373-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy.
|
|
pubmed:affiliation |
Ghent University Hospital, Ghent, Belgium.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
